Skin Analytics

The company's core product is DERM (Deep Ensemble for the Recognition of Malignancy), an AI as a Medical Device (AIaMD). It is the world's first legally authorized AI to make autonomous clinical decisions on skin cancer without requiring human review, holding a Class III CE mark under European regulations and a Class IIa UKCA mark. The technology works by analyzing dermatoscopic images of skin lesions, captured via a smartphone with a special lens, to triage cases into malignant, pre-malignant, or benign in milliseconds. This allows healthcare systems to safely discharge benign cases, reduce the need for biopsies, and fast-track high-risk patients to specialists.

Skin Analytics primarily serves national health systems and private insurers. Its main client is the UK's National Health Service (NHS), where it has been deployed in over 25 organizations since 2020. The company also provides remote skin assessment services for Bupa and Vitality. The business model involves integrating DERM into existing teledermatology pathways to enhance efficiency and tackle patient backlogs amid a global shortage of dermatologists. The service is priced on a per-case or population basis, demonstrating significant cost savings for healthcare providers by reducing the number of face-to-face appointments.

The company has demonstrated considerable impact, having assessed over 170,000 NHS patients and identified more than 15,500 cancers. Pathways using DERM have helped some NHS partners avoid up to 95% of face-to-face urgent referral appointments. The AI's performance has been validated in real-world use, showing a 99.8% Negative Predictive Value (NPV) in ruling out cancer, which is slightly higher than face-to-face dermatologist evaluations. Following a successful Series B funding round of €17.5 million in 2025, Skin Analytics is planning to expand its services into Europe, Australia, and the US market.